Trials / Recruiting
RecruitingNCT06591819
Hypofractionated WPPT With HDR Boost
Safety of Hypofractionated Whole-Pelvis Proton Therapy With HDR Boost
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost | Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions. |
Timeline
- Start date
- 2025-01-15
- Primary completion
- 2034-01-01
- Completion
- 2035-12-01
- First posted
- 2024-09-19
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06591819. Inclusion in this directory is not an endorsement.